Cargando…
H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
BACKGROUND: Treatment of multiple sclerosis (MS) relapses can be complex in patients with concomitant diabetes. Corticosteroids and adrenocorticotropic hormones are known to cause alterations in glucose tolerance. Many patients have poor tolerability to therapy, necessitating alternative treatment o...
Autor principal: | Kutz, Christen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935834/ https://www.ncbi.nlm.nih.gov/pubmed/27433309 http://dx.doi.org/10.1177/2040622316644481 |
Ejemplares similares
-
A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020) -
Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016) -
Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases
por: Markell, Mariana, et al.
Publicado: (2019) -
Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016) -
Repository Corticotropin Injection (Acthar(®) Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study
por: Wirta, David, et al.
Publicado: (2021)